BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21454218)

  • 21. Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea.
    Kim SJ; Lee GY; Jang HR; Choi JO; Kim JS; Kim HJ; Lee SY; Min JH; Jeon ES; Kim K
    Amyloid; 2013 Dec; 20(4):204-11. PubMed ID: 23914780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients.
    Garces-Sanchez M; Dyck PJ; Kyle RA; Zeldenrust S; Wu Y; Ladha SS; Klein CJ
    Muscle Nerve; 2008 Apr; 37(4):490-5. PubMed ID: 18236455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
    Leung N; Dispenzieri A; Lacy MQ; Kumar SK; Hayman SR; Fervenza FC; Cha SS; Gertz MA
    Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.
    Dispenzieri A; Seenithamby K; Lacy MQ; Kumar SK; Buadi FK; Hayman SR; Dingli D; Litzow MR; Gastineau DA; Inwards DJ; Micallef IN; Ansell SM; Johnston PB; Porrata LF; Patnaik MM; Hogan WJ; Gertz MA
    Bone Marrow Transplant; 2013 Oct; 48(10):1302-7. PubMed ID: 23604010
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2013 May; 88(5):416-25. PubMed ID: 23605846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis.
    Dispenzieri A; Gertz MA; Kyle RA; Lacy MQ; Burritt MF; Therneau TM; Greipp PR; Witzig TE; Lust JA; Rajkumar SV; Fonseca R; Zeldenrust SR; McGregor CG; Jaffe AS
    J Clin Oncol; 2004 Sep; 22(18):3751-7. PubMed ID: 15365071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A single-centre cohort of patients with systemic light chain AL-amyloidosis treated with conventional chemotherapy or with high-dose chemotherapy and autologous stem cell transplantation.
    Raschle J; Banz Y; Suter T; Pabst T
    Swiss Med Wkly; 2014 Feb; 144():w13922. PubMed ID: 24554372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring.
    Goldsmith YB; Liu J; Chou J; Hoffman J; Comenzo RL; Steingart RM
    Am J Cardiol; 2009 Oct; 104(7):990-4. PubMed ID: 19766769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.
    Roussel M; Sachchithanantham S; Gibbs SD; Venner CP; Pinney JH; Gillmore JD; Lachmann HJ; Hawkins PN; Wechalekar AD
    Br J Haematol; 2013 Sep; 162(6):856-8. PubMed ID: 23773011
    [No Abstract]   [Full Text] [Related]  

  • 30. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
    Bahlis NJ; Lazarus HM
    Bone Marrow Transplant; 2006 Jul; 38(1):7-15. PubMed ID: 16715110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.
    Gertz MA; Leung N; Lacy MQ; Dispenzieri A; Zeldenrust SR; Hayman SR; Buadi FK; Dingli D; Greipp PR; Kumar SK; Lust JA; Rajkumar SV; Russell SJ; Witzig TE
    Nephrol Dial Transplant; 2009 Oct; 24(10):3132-7. PubMed ID: 19403931
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Amyloid light chain amyloidosis].
    Suzuki K; Shimizu T
    Brain Nerve; 2014 Jul; 66(7):795-809. PubMed ID: 24998824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant.
    Warsame R; Bang SM; Kumar SK; Gertz MA; Lacy MQ; Buadi F; Dingli D; Hayman SR; Kapoor P; Kyle RA; Leung N; Lust JA; Russell SJ; Witzig TE; Zeldenrust SR; Rajkumar SV; Dispenzieri A
    Eur J Haematol; 2014 Jun; 92(6):485-90. PubMed ID: 24502602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Light chain amyloidosis--clinical symptoms, update diagnosis, and treatment].
    CharliƄski G; Jurczyszyn A; Wiktor-Jedrzejczak W
    Przegl Lek; 2014; 71(2):102-9. PubMed ID: 25016786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders.
    Morra E; Cesana C; Klersy C; Barbarano L; Varettoni M; Cavanna L; Canesi B; Tresoldi E; Miqueleiz S; Bernuzzi P; Nosari AM; Lazzarino M
    Leukemia; 2004 Sep; 18(9):1512-7. PubMed ID: 15322559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [kappa-light chain amyloidosis of the liver, a rare cause of liver enzyme elevation].
    Borde JP; Link R; Offensperger WB
    Dtsch Med Wochenschr; 2008 May; 133(21):1116-20. PubMed ID: 18478504
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
    Comenzo RL
    Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.